Bing Bai

Bing Bai

Auto-generated profile, based on publicly available information

Bing Bai

University of Alberta

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Nanoscale
Verified
Journal Article
Closed access
PDF file
ZKZhiwen Kang
Zhiwen Kang
XWXiaochen Wang
Xiaochen Wang
DWDan Wang
Dan Wang
BBBing Bai
Bing Bai
YZYafei Zhao
Yafei Zhao
HSHuishan Shang
Huishan Shang
Slow oxygen reduction reaction (ORR) kinetics is the main factor restricting the development of fuel cells and metal–air batteries. Carbon-based single-atom catalysts (SACs) have the advantages of high electrical conductivity, maximal atom utilization, and high mass activity, thus showing great potential in exploring low-cost and high-efficiency ORR catalysts. For carbon-based SACs, the defects in the carbon support, the coordination of non-metallic heteroatoms, and the coordination number have a great influence on the adsorption of the reaction intermediates, thus significantly affecting the catalytic performance. Consequently, it is of vital importance to summarize the impacts of atomic coordination on the ORR. In this review, we focus on the regulation of the central atoms and coordination atoms of carbon-based SACs for the ORR. The survey involves various SACs, from noble metals (Pt) to transition metals (Fe, Co, Ni, Cu, etc.) and major group metals (Mg, Bi, etc.). At the same time, the influence of defects in the carbon support, the coordination of non-metallic heteroatoms (such as B, N, P, S, O, Cl, etc.), and the coordination number of the well-defined SACs on the ORR were put forward. Then, the impact of the neighboring metal monomers for SACs on the ORR performance is discussed. Finally, the current challenges and prospects for the future development of carbon-based SACs in coordination chemistry are presented.

27 December 2024 in ChemMedChem
Verified
Journal Article
Open access
BBBing Bai
Bing Bai
AKAppan Srinivas Kandadai
Appan Srinivas Kandadai
MHMostofa Hena
Mostofa Hena
ABAlexandr Belovodskiy
Alexandr Belovodskiy
JSJohn Shen
John Shen
JNJames A. Nieman
James A. Nieman
The development of non‐nucleoside inhibitors targeting human cytomegalovirus (HCMV) polymerase presents a promising approach for enhancing therapeutic treatment for patients with sustained HCMV viremia. A series of non‐nucleoside HCMV DNA polymerase inhibitors with various substitution groups at 2‐postition of the novel pyrido[2,3‐b]pyrazine core was synthesized and investigated. The study focused on optimizing HCMV polymerase inhibition while minimizing off‐target inhibition of human ether‐à‐go‐go (hERG) ion channel. Several compounds exhibited strong antiviral activity against HCMV (typical EC50<1 μM), with favorable cytotoxicity profiles. A potent lead compound, 27, with an EC50 of 0.33 μM and improved aqueous solubility was identified. Further antiviral assessments revealed the potential of select compounds to target a broad spectrum of herpesviruses, including herpes simplex virus (HSV‐1, HSV‐2) and Epstein‐Barr virus (EBV).

16 July 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PCPu Chen
Pu Chen
USUlrike Strunk
Ulrike Strunk
EAElena Arutyunova
Elena Arutyunova
JLJimmy Lu
Jimmy Lu
SCSizhu Amelia Chen
Sizhu Amelia Chen
MLM Joanne Lemieux
M Joanne Lemieux